Compare CNF & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNF | NSRX |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | China | Israel |
| Employees | N/A | 7 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 25.8M |
| IPO Year | 2018 | N/A |
| Metric | CNF | NSRX |
|---|---|---|
| Price | $2.85 | $3.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 2.8K | ★ 93.3K |
| Earning Date | 05-05-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $1.98 |
| 52 Week High | $24.00 | $9.99 |
| Indicator | CNF | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 58.74 |
| Support Level | $2.72 | $2.04 |
| Resistance Level | $5.13 | $5.20 |
| Average True Range (ATR) | 0.19 | 0.38 |
| MACD | 0.06 | 0.26 |
| Stochastic Oscillator | 25.87 | 61.51 |
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.